株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

多発性硬化症:主要18市場の予測 2017-2027年

Epiomic Epidemiology Series: Multiple Sclerosis Forecast in 18 Major Markets 2017-2027

発行 Black Swan Analysis 商品コード 425865
出版日 ページ情報 英文 98 Pages
即納可能
価格
本日の銀行送金レート: 1USD=113.38円で換算しております。
Back to Top
多発性硬化症:主要18市場の予測 2017-2027年 Epiomic Epidemiology Series: Multiple Sclerosis Forecast in 18 Major Markets 2017-2027
出版日: 2017年01月01日 ページ情報: 英文 98 Pages
概要

当レポートでは、主要18市場 (米国、カナダ、フランス、ドイツ、イタリア、スペイン、英国、トルコ、オーストラリア、ポーランド、ルーマニア、ロシア、メキシコ、アルゼンチン、ブラジル、日本、インド、中国) における多発性硬化症の現在の患者数 (性別、年齢コホート別) について調査分析し、現在の有病率のほか、疾患の概要、危険因子、疾患の診断と予後、主な症状や合併症など、体系的な情報を提供しています。

図表

イントロダクション

病因

危険因子と予防

疾患の診断

変異:地域/民族別

疾患予後と臨床経過

疾患に関連する主な合併症/特徴

患者数の定量化方法

多発性硬化症の最大有病者数

多発性硬化症患者の特徴

  • 多発性硬化症のサブタイプ
  • 重症度
  • 腹痛
  • 睡眠障害
  • 痙性
  • 尿・膀胱障害

多発性硬化症患者の併存疾患

略語

関連出版

患者ベースのオンラインデータベース

患者ベースの製品

オンライン価格データ・プラットフォーム

参考文献

付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: MLTS0010117

Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on Multiple Sclerosis in 18 Major Markets.

Multiple Sclerosis (MS) (also known as disseminated sclerosis) is a chronic, inflammatory demyelinating immune-mediated disease of the central nervous system (CNS). MS is characterised by the formation of lesions in the central nervous system, the destruction of the myelin sheath (insulation surrounding the nerve fibres of the CNS) and inflammation. Patients can exhibit a broad range of signs and symptoms associated with neural damage and dysfunction.

This report provides the current prevalent population for Multiple Sclerosis across 18 Major Markets (USA, Canada, France, Germany, Italy, Spain, UK, Turkey, Australia, Poland, Romania, Russia, Mexico, Argentina, Brazil, Japan, India, China) split by gender and 5-year age cohort. Along with the current prevalence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the analysis team at Black Swan, several of the main symptoms and co-morbidities of Multiple Sclerosis have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Main symptoms and co-morbidities for Multiple Sclerosis include:

  • Osteoporosis
  • Osteopenia
  • Diabetes
  • Hyperlipidaemia
  • Hypertension
  • Uveitis
  • Muscle stiffness or spasms
  • Paralysis (typically of the legs)
  • Problems with the bladder/bowel/sexual function
  • Mental changes (forgetfulness/mood swings)
  • Depression
  • Epilepsy

This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information from patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.

Reason to buy

  • Able to quantify patient populations in global Multiple Sclerosis market to target the development of future products, pricing strategies and launch plans.
  • Gain further insight into the prevalence of the subdivided types of Multiple Sclerosis and identify patient segments with high potential.
  • Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
  • Provide a level of understanding on the impact from specific co-morbid conditions on Multiple Sclerosis prevalent population.
  • Identify sub-populations within Multiple Sclerosis which require treatment.
  • Gain an understanding of the specific markets that have the largest number of Multiple Sclerosis patients.

Table of Contents

  • List of Tables and Figures
  • Introduction
  • Cause of the Disease
  • Risk Factors & Prevention
  • Diagnosis of the Disease
  • Variation by Geography/Ethnicity
  • Disease Prognosis & Clinical Course
  • Key comorbid conditions associated with the disease
  • Methodology for quantification of patient numbers
  • Top-line prevalence for Multiple Sclerosis
    • Diagnosis certainty
  • Features of Multiple Sclerosis patients
    • Multiple Sclerosis Subtype
    • Disability severity
    • Abdominal pain
    • Sleep problems
    • Spasticity
    • Urinary and bladder problems
  • Comorbidities in Multiple Sclerosis patients
    • Features of MS patients with relapsing- remitting MS
    • Features of MS patients with Secondary Progressive MS
    • Features of MS patients with Primary Progressive MS
    • Features of MS patients with Primary Relapsing MS
  • Abbreviations used in the report
  • Other Black Swan Analysis Publications
  • Black Swan Analysis Online Patient-Based Databases
  • Patient-Based Offering
  • Online Pricing Data and Platforms
  • References
  • Appendix

List of Figures

  • Demyelination in MS

List of Tables

  • The McDonald criteria
  • Features and characteristics of the subtypes of MS
  • Prevalence of Multiple Sclerosis, total (000s)
  • Prevalence of Multiple Sclerosis, males (000s)
  • Prevalence of Multiple Sclerosis, females (000s)
  • Diagnosis Certainty of MS, total (000s)
  • MS subtype, total (000s)
  • Disability severity of MS patients, total (000s)
  • Severity of abdominal pain in MS patients, total (000s)
  • Severity of sleep problems in MS patients, total (000s)
  • Degree of Spasticity In MS patients, total (000s)
  • Nocturia in patients with MS, total (000s)
  • Activity leakage in MS patients, total (000s)
  • Urgency leakage in MS patients, total (000s)
  • MS patients with osteopenia, total (000s)
  • MS patients with diabetes, total (000s)
  • MS patients with hyperlipidaemia, total (000s)
  • MS patients with hypertension, total (000s)
  • MS patients with persistent bothersome pain, total (000s)
  • MS patients with RLS, total (000s)
  • MS patients with bone fractures after 3 yrs, total (000s)
  • MS current smokers, total (000s)
  • MS patients with neuropathic pain, total (000s)
  • MS patients with severe fatigue, total (000s)
  • RRMS with trigeminal neuralgia, total (000s)
  • RRMS with Lhermitte's sign, total (000s)
  • RRMS with dysaesthesia, total (000s)
  • RRMS with painful muscle spasms, total (000s)
  • RRMS with back pain, total (000s)
  • RRMS with migraine, total (000s)
  • SRMS with trigeminal neuralgia, total (000s)
  • SPMS with Lhermitte's sign, total (000s)
  • SPMS with dysaesthesia, total (000s)
  • SPMS with painful muscle spasms, total (000s)
  • SPMS with back pain, total (000s)
  • SPMS with migraine, total (000s)
  • PPMS with trigeminal neuralgia, total (000s)
  • PPMS with Lhermitte's sign, total (000s)
  • PPMS with dysaesthesia, total (000s)
  • PPMS with painful muscle spasms, total (000s)
  • PPMS with back pain, total (000s)
  • PPMS with migraine, total (000s)
  • PRMS with trigeminal neuralgia, total (000s)
  • PRMS with Lhermitte's sign, total (000s)
  • PRMS with dysaesthesia, total (000s)
  • PRMS with painful muscle spasms, total (000s)
  • PRMS with back pain, total (000s)
  • PRMS with migraine, total (000s)
  • Abbreviations and Acronyms used in the report
  • USA Prevalence of Multiple Sclerosis by 5-yr age cohort, males (000s)
  • USA Prevalence of Multiple Sclerosis by 5-yr age cohort, females (000s)
  • Canada Prevalence of Multiple Sclerosis by 5-yr age cohort, males (000s)
  • Canada Prevalence of Multiple Sclerosis by 5-yr age cohort, females (000s)
  • France Prevalence of Multiple Sclerosis by 5-yr age cohort, males (000s)
  • France Prevalence of Multiple Sclerosis by 5-yr age cohort, females (000s)
  • Germany Prevalence of Multiple Sclerosis by 5-yr age cohort, males (000s)
  • Germany Prevalence of Multiple Sclerosis by 5-yr age cohort, females (000s)
  • Italy Prevalence of Multiple Sclerosis by 5-yr age cohort, males (000s)
  • Italy Prevalence of Multiple Sclerosis by 5-yr age cohort, females (000s)
  • Spain Prevalence of Multiple Sclerosis by 5-yr age cohort, males (000s)
  • Spain Prevalence of Multiple Sclerosis by 5-yr age cohort, females (000s)
  • UK Prevalence of Multiple Sclerosis by 5-yr age cohort, males (000s)
  • UK Prevalence of Multiple Sclerosis by 5-yr age cohort, females (000s)
  • Turkey Prevalence of Multiple Sclerosis by 5-yr age cohort, males (000s)
  • Turkey Prevalence of Multiple Sclerosis by 5-yr age cohort, females (000s)
  • Australia Prevalence of Multiple Sclerosis by 5-yr age cohort, males (000s)
  • Australia Prevalence of Multiple Sclerosis by 5-yr age cohort, females (000s)
  • Poland Prevalence of Multiple Sclerosis by 5-yr age cohort, males (000s)
  • Poland Prevalence of Multiple Sclerosis by 5-yr age cohort, females (000s)
  • Romania Prevalence of Multiple Sclerosis by 5-yr age cohort, males (000s)
  • Romania Prevalence of Acne Vulgaris by 5-yr age cohort, females (000s)
  • Russia Prevalence of Multiple Sclerosis by 5-yr age cohort, males (000s)
  • Russia Prevalence of Multiple Sclerosis by 5-yr age cohort, females (000s)
  • Brazil Prevalence of Multiple Sclerosis by 5-yr age cohort, males (000s)
  • Brazil Prevalence of Multiple Sclerosis by 5-yr age cohort, females (000s)
  • Mexico Prevalence of Multiple Sclerosis by 5-yr age cohort, males (000s)
  • Mexico Prevalence of Multiple Sclerosis by 5-yr age cohort, females (000s)
  • Argentina Prevalence of Multiple Sclerosis by 5-yr age cohort, males (000s)
  • Argentina Prevalence of Multiple Sclerosis by 5-yr age cohort, females (000s)
  • Japan Prevalence of Multiple Sclerosis by 5-yr age cohort, males (000s)
  • Japan Prevalence of Multiple Sclerosis by 5-yr age cohort, females (000s)
  • India Prevalence of Multiple Sclerosis by 5-yr age cohort, males (000s)
  • India Prevalence of Multiple Sclerosis by 5-yr age cohort, females (000s)
  • China Prevalence of Multiple Sclerosis by 5-yr age cohort, males (000s)
  • China Prevalence of Multiple Sclerosis by 5-yr age cohort, females (000s)
Back to Top